Gene Remedy-Centered Bluebird Bio Receives Rival Takeover Provide, Inventory Jumps – bluebird bio (NASDAQ:BLUE)

Bluebird Bio, Inc. BLUE obtained an unsolicited, non-binding written proposal from Ayrmid Ltd. on Friday.

Ayrmid has proposed to accumulate Bluebird for an upfront money cost of $4.50 per share and a one-time contingent worth proper of $6.84 per share payable upon attaining a internet gross sales milestone.

In February 2025, Bluebird entered right into a definitive settlement with Carlyle and SK Capital Companions to be acquired and brought non-public for $3.00 per share in money and a one-time contingent worth proper of $6.84 per share payable upon achievement of a internet gross sales milestone.

Additionally Learn: FDA-Accredited Sickle Cell Therapies From Bluebird Bio And Vertex Be a part of Medicaid Innovation Program

Bluebird beforehand engaged in discussions with Ayrmid as a part of its complete overview of strategic alternate options.

Ayrmid didn’t submit any proposal to Bluebird throughout that course of.

In line with its fiduciary duties, the Bluebird Board of Administrators is reviewing the Ayrmid Proposal in session with its authorized and monetary advisors.

In November 2024, the FDA raised issues about life-threatening hematologic malignancies in sufferers handled with Bluebird Bio’s Skysona (elivaldogene autotemcel), a gene remedy for early, lively cerebral adrenoleukodystrophy (CALD).

The company has obtained experiences of myelodysplastic syndrome and acute myeloid leukemia linked to Skysona, with instances rising 14 to 92 months post-treatment throughout scientific trials.

Worth Motion: BLUE inventory is up 7.84% at $4.40 on the final verify Monday.

Learn Subsequent:

Picture: Shutterstock